Co-Authors
This is a "connection" page, showing publications co-authored by KELLY K HUNT and ALEXANDER LAZAR.
Connection Strength
1.263
-
Analysis of prognostic factors impacting oncologic outcomes after neoadjuvant tyrosine kinase inhibitor therapy for gastrointestinal stromal tumors. Ann Surg Oncol. 2014 Aug; 21(8):2499-505.
Score: 0.119
-
Integrative genomic characterization and a genomic staging system for gastrointestinal stromal tumors. Cancer. 2011 Jan 15; 117(2):380-9.
Score: 0.093
-
Plasma DNA Methylation-Based Biomarkers for MPNST Detection in Patients With Neurofibromatosis Type 1. Mol Carcinog. 2025 Jan; 64(1):44-56.
Score: 0.062
-
Patterns of Care and Outcomes of Patients with Small Gastrointestinal Stromal Tumors at a High-Volume Sarcoma Center. Ann Surg Oncol. 2024 Dec; 31(13):9258-9264.
Score: 0.061
-
Clinical Variables Influencing Outcomes in Patients with Atypical Intradermal Smooth Muscle Neoplasms (Formerly Cutaneous Leiomyosarcomas): Single-Institution Study of 95 Surgical Patients. Ann Surg Oncol. 2024 Nov; 31(12):7950-7956.
Score: 0.061
-
A randomized, non-comparative phase 2 study of neoadjuvant immune-checkpoint blockade in retroperitoneal dedifferentiated liposarcoma and extremity/truncal undifferentiated pleomorphic sarcoma. Nat Cancer. 2024 Apr; 5(4):625-641.
Score: 0.059
-
Sequential Targeting of Retinoblastoma and DNA Synthesis Pathways Is a Therapeutic Strategy for Sarcomas That Can Be Monitored in Real Time. Cancer Res. 2023 03 15; 83(6):939-955.
Score: 0.055
-
Re-excision After Unplanned Excision of Soft Tissue Sarcoma is Associated with High Morbidity and Limited Pathologic Identification of Residual Disease. Ann Surg Oncol. 2023 Jan; 30(1):480-489.
Score: 0.053
-
Real-world use of palbociclib monotherapy in retroperitoneal liposarcomas at a large volume sarcoma center. Int J Cancer. 2022 06 15; 150(12):2012-2024.
Score: 0.051
-
Enhancer reprogramming in PRC2-deficient malignant peripheral nerve sheath tumors induces a targetable de-differentiated state. Acta Neuropathol. 2021 09; 142(3):565-590.
Score: 0.049
-
Comparison of Cancer Prevalence in Patients With Neurofibromatosis Type 1 at an Academic Cancer Center vs in the General Population From 1985 to 2020. JAMA Netw Open. 2021 03 01; 4(3):e210945.
Score: 0.048
-
Phase II study of neoadjuvant checkpoint blockade in patients with surgically resectable undifferentiated pleomorphic sarcoma and dedifferentiated liposarcoma. BMC Cancer. 2018 Sep 24; 18(1):913.
Score: 0.041
-
Identification of preoperative factors associated with outcomes following surgical management of intra-abdominal recurrent or metastatic GIST following neoadjuvant tyrosine kinase inhibitor therapy. J Surg Oncol. 2018 Apr; 117(5):879-885.
Score: 0.039
-
Analysis of the immune infiltrate in undifferentiated pleomorphic sarcoma of the extremity and trunk in response to radiotherapy: Rationale for combination neoadjuvant immune checkpoint inhibition and radiotherapy. Oncoimmunology. 2018; 7(2):e1385689.
Score: 0.038
-
Clinical Observations and Molecular Variables of Primary Vascular Leiomyosarcoma. JAMA Surg. 2016 Apr; 151(4):347-54.
Score: 0.034
-
Analysis of Clinical and Molecular Factors Impacting Oncologic Outcomes in Undifferentiated Pleomorphic Sarcoma. Ann Surg Oncol. 2016 07; 23(7):2220-8.
Score: 0.034
-
Phase 1 adaptive dose-finding study of neoadjuvant gemcitabine combined with radiation therapy for patients with high-risk extremity and trunk soft tissue sarcoma. Cancer. 2015 Oct 15; 121(20):3659-67.
Score: 0.032
-
Radiation-Associated Undifferentiated Pleomorphic Sarcoma is Associated with Worse Clinical Outcomes than Sporadic Lesions. Ann Surg Oncol. 2015 Nov; 22(12):3913-20.
Score: 0.032
-
Mesenchymal to epithelial transition in sarcomas. Eur J Cancer. 2014 Feb; 50(3):593-601.
Score: 0.029
-
Uterine leiomyosarcoma management, outcome, and associated molecular biomarkers: a single institution's experience. Ann Surg Oncol. 2013 Jul; 20(7):2364-72.
Score: 0.027
-
Long-term outcomes in patients with radiation-associated angiosarcomas of the breast following surgery and radiotherapy for breast cancer. Ann Surg Oncol. 2013 Apr; 20(4):1267-74.
Score: 0.027
-
Dual targeting of mTOR and aurora-A kinase for the treatment of uterine Leiomyosarcoma. Clin Cancer Res. 2012 Sep 01; 18(17):4633-45.
Score: 0.026
-
Integrated proteomics and genomics analysis reveals a novel mesenchymal to epithelial reverting transition in leiomyosarcoma through regulation of slug. Mol Cell Proteomics. 2010 Nov; 9(11):2405-13.
Score: 0.023
-
Angiosarcoma: clinical and molecular insights. Ann Surg. 2010 Jun; 251(6):1098-106.
Score: 0.023
-
Clinical outcomes of molecularly confirmed clear cell sarcoma from a single institution and in comparison with data from the Surveillance, Epidemiology, and End Results registry. Cancer. 2009 Jul 01; 115(13):2971-9.
Score: 0.021
-
Complete soft tissue sarcoma resection is a viable treatment option for select elderly patients. Ann Surg Oncol. 2009 Sep; 16(9):2579-86.
Score: 0.021
-
Outcome of locally recurrent and metastatic angiosarcoma. Ann Surg Oncol. 2009 Sep; 16(9):2502-9.
Score: 0.021
-
Increased vascular endothelial growth factor-C expression is insufficient to induce lymphatic metastasis in human soft-tissue sarcomas. Clin Cancer Res. 2009 Apr 15; 15(8):2637-46.
Score: 0.021
-
A randomized, phase II study of preoperative plus postoperative imatinib in GIST: evidence of rapid radiographic response and temporal induction of tumor cell apoptosis. Ann Surg Oncol. 2009 Apr; 16(4):910-9.
Score: 0.020
-
Genetic aberrations of gastrointestinal stromal tumors. Cancer. 2008 Oct 01; 113(7):1532-43.
Score: 0.020
-
Genetic aberrations in soft tissue leiomyosarcoma. Cancer Lett. 2009 Mar 08; 275(1):1-8.
Score: 0.020